UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K


CURRENT REPORT

Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 19, 2024



Navient Corporation
(Exact name of registrant as specified in its charter)



Delaware
 
001-36228
 
46-4054283
(State or other jurisdiction of incorporation)
 
(Commission File Number)
 
(IRS Employer Identification No.)

13865 Sunrise Valley Drive, Herndon, Virginia
 
20171
(Address of principal executive offices)
 
(Zip Code)

Registrant’s telephone number, including area code (703) 810-3000

Not Applicable
(Former name or former address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common stock, par value $.01 per share
NAVI
The Nasdaq Global Select Market
6% Senior Notes due December 15, 2043
JSM
The Nasdaq Global Select Market
Preferred Stock Purchase Rights
None
The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐



Item 2.01.
Completion of Acquisition or Disposition of Assets.

On September 19, 2024, Navient Corporation (the “Company”) completed the sale of its equity interests in Xtend Healthcare, LLC, which comprised the Company's healthcare services business in its Business Processing segment to Coding Solutions Acquisition, Inc. (CorroHealth) for $369 million ($365 million of total consideration, plus an estimated $4 million of working capital and other adjustments to the contractual price).

The unaudited pro forma financial information giving effect to the sale transaction is filed herewith as Exhibit 99.1.

Item 9.01.
Financial Statements and Exhibits.

(b) Pro Forma Financial Information.

The following unaudited pro forma financial information of the Company is attached hereto as Exhibit 99.1 and is incorporated herein by reference:


Unaudited Pro Forma Condensed Consolidated Balance Sheet as of June 30, 2024.

Unaudited Pro Forma Condensed Consolidated Statements of Income for the year ended December 31, 2023 and for the six months ended June 30, 2024.

Notes to the Unaudited Pro Forma Condensed Consolidated Financial Statements.

(d) Exhibits.

Exhibit
Number
 
Description
 
Unaudited Pro Forma Condensed Consolidated Financial Statements.
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document).


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
NAVIENT CORPORATION
   
 
By:
/s/ Joe Fisher
   
Name:
 Joe Fisher
   
Title:
Chief Financial Officer
 


Date: September 20, 2024






Exhibit 99.1

NAVIENT CORPORATION
 
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
 
On September 19, 2024, Navient Corporation (“Navient”) completed the sale of its equity interests in Xtend Healthcare, LLC, which comprised Navient’s Healthcare Services business in Navient’s Business Processing segment, to Coding Solutions Acquisition, Inc. (“CorroHealth”) for $369 million ($365 million of total consideration, plus an estimated $4 million of working capital and other adjustments to the contractual price) (the “Healthcare Services sale transaction”).
 
The following unaudited pro forma condensed consolidated balance sheet as of June 30, 2024, is presented as if the Healthcare Services sale transaction had occurred on June 30, 2024.
 
The unaudited pro forma condensed consolidated statements of income for the year ended December 31, 2023, and the six months ended June 30, 2024, are presented as if the Healthcare Services sale transaction had occurred on January 1, 2023. The estimated gain on sale in connection with the Healthcare Services sale transaction is reflected in the unaudited pro forma condensed consolidated balance sheet within equity. The estimated gain on sale of $216 million is not reflected in the unaudited pro forma condensed consolidated statements of income as it does not have a continuing impact on Navient’s results.
 
The unaudited pro forma condensed consolidated financial information has been prepared from Navient's historical accounting records and, in accordance with Article 11 of SEC Regulation S-X, is subject to the assumptions and adjustments described in the accompanying notes. These assumptions and adjustments are based on information presently available. Actual adjustments may differ materially from the information presented. The unaudited pro forma condensed consolidated financial statements are based on the historical financial statements of Navient for each period presented and in the opinion of Navient management, all adjustments, and disclosures necessary for a fair presentation of the pro forma data have been made.
 
The unaudited pro forma condensed consolidated financial information includes pro forma adjustments which reflect transactions and events that (a) are directly attributable to the Healthcare Services sale transaction, (b) are factually supportable and (c) with respect to the statements of income, have a continuing impact on consolidated results. The pro forma adjustments are described in the accompanying notes to the unaudited pro forma condensed consolidated financial statements. The unaudited pro forma condensed consolidated financial information does not reflect future events that may occur after the Healthcare Services sale transaction, including any potential future cost savings that may be achieved.
 
These unaudited pro forma condensed consolidated financial statements are presented for illustrative purposes only and are not necessarily indicative of the results of operations or financial condition that would have been achieved had events reflected been completed as of the dates indicated or of the results that may be obtained in the future. These unaudited pro forma condensed consolidated financial statements and the notes thereto should be read together with Navient’s audited consolidated financial statements and the notes thereto as of and for the year ended December 31, 2023, and Management’s Discussion and Analysis included in Navient’s Annual Report on Form 10-K for the year ended December 31, 2023, as well as Navient’s unaudited consolidated financial statements and the notes thereto as of and for the six months ended June 30, 2024, and Management’s Discussion and Analysis included in Navient’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2024.

1

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET
As of June 30, 2024 (in millions)

   
As
   
Pro Forma
         
   
Reported
   
Adjustments
     
Pro Forma
 
Assets
                   
FFELP Loans
 
$
32,940
   
$
-
     
$
32,940
 
Private Education Loans
   
16,238
     
-
       
16,238
 
Investments
   
132
     
-
       
132
 
Cash and cash equivalents
   
1,088
     
362
 
 (A)
   
1,450
 
Restricted cash and cash equivalents
   
2,918
     
-
       
2,918
 
Goodwill and acquired intangible assets, net
   
690
     
(113
)
 (B)
   
577
 
Other assets
   
2,616
     
(41
)
 (B)
   
2,575
 
Total assets
 
$
56,622
   
$
208
     
$
56,830
 
                           
Liabilities
                         
Short-term borrowings
 
$
5,326
   
$
-
     
$
5,326
 
Long-term borrowings
   
47,545
     
-
       
47,545
 
Other liabilities
   
1,003
     
42
 
 (B) (C)
   
1,045
 
Total liabilities
   
53,874
     
42
       
53,916
 
                           
Equity
                         
Total equity
   
2,748
     
166
 
 (D)
   
2,914
 
                           
Total liabilities and equity
 
$
56,622
   
$
208
     
$
56,830
 

2

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME
For the year ended December 31, 2023 (in millions, except per share amounts)

   
As
   
Pro Forma
         
   
Reported
   
Adjustments
     
Pro Forma
 
Total interest income
 
$
4,419
   
$
-
     
$
4,419
 
Total interest expense
   
3,557
     
-
       
3,557
 
Net interest income
   
862
     
-
       
862
 
Less: provisions for loan losses
   
123
     
-
       
123
 
Net interest income after provisions for loan losses
   
739
     
-
       
739
 
 
                         
Other income (loss):
                         
Servicing revenue
   
64
     
-
       
64
 
Asset recovery and business processing revenue
   
321
     
(121
)
 (E)
   
200
 
Other income
   
21
     
-
       
21
 
Losses on debt repurchases
   
(8
)
   
-
       
(8
)
Gains (losses) on derivative and hedging activities, net
   
11
     
-
       
11
 
Total other income
   
409
     
(121
)
     
288
 
 
                         
Expenses:
                         
Salaries and benefits
   
401
     
(80
)
 (E)
   
321
 
Other operating expenses
   
399
     
(21
)
 (E)
   
378
 
Total operating expenses
    800
      (101
)       699
 
Goodwill and acquired intangible asset impairment and amortization expense
   
10
     
(4
)
 (E)
   
6
 
Restructuring/other reorganization expenses
   
25
     
(2
)
 (E)
   
23
 
Total expenses
   
835
     
(107
)
     
728
 
Income before income tax expense
   
313
     
(14
)
     
299
 
Income tax expense
   
85
     
(3
)
 (F)
   
82
 
Net income
 
$
228
   
$
(11
)
   
$
217
 
 
                         
Per Share Amounts:
                         
 
                         
Basic earnings per common share
 
$
1.87
              
$
1.78
 
Average common shares outstanding
   
122
               
122
 
 
                         
Diluted earnings per common share
 
$
1.85
              
$
1.76
 
Average common and common equivalent shares outstanding
   
123
               
123
 

3

UNAUDITED PRO FORMA CONDENSED CONSOLIDATED STATEMENT OF INCOME
For the six months ended June 30, 2024 (in millions, except per share amounts)

 
 
 
As
   
Pro Forma
         
 
 
Reported
   
Adjustments
     
Pro Forma
 
Total interest income
 
$
2,000
   
$
-
     
$
2,000
 
Total interest expense
   
1,718
     
-
       
1,718
 
Net interest income
   
282
     
-
       
282
 
Less: provisions for loan losses
   
26
     
-
       
26
 
Net interest income after provisions for loan losses
   
256
     
-
       
256
 
 
                         
Other income (loss):
                         
Servicing revenue
   
35
     
-
       
35
 
Asset recovery and business processing revenue
   
158
     
(60
)
 (E)
   
98
 
Other income
   
13
     
-
       
13
 
Gains (losses) on derivative and hedging activities, net
   
46
     
-
       
46
 
Total other income
   
252
     
(60
)
     
192
 
 
                         
Expenses:
                         
Salaries and benefits
   
188
     
(38
)
 (E)
   
150
 
Other operating expenses
   
162
     
(9
)
 (E)
   
153
 
Total operating expenses
    350
      (47
)       303
 
Goodwill and acquired intangible asset impairment and amortization expense
   
5
     
(2
)
 (E)
   
3
 
Restructuring/other reorganization expenses
   
17
     
-
 
 (E)
   
17
 
Total expenses
   
372
     
(49
)
     
323
 
Income before income tax expense
   
136
     
(11
)
     
125
 
Income tax expense
   
27
     
(3
)
 (F)
   
24
 
Net income
 
$
109
   
$
(8
)
   
$
101
 
 
                         
Per Share Amounts:
                         
 
                         
Basic earnings per share
 
$
0.98
              
$
0.90
 
Average common shares outstanding
   
112
               
112
 
 
                         
Diluted earnings per share
 
$
0.97
              
$
0.89
 
Average common and common equivalent shares outstanding
   
113
               
113
 

4

NOTES TO THE UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(A)  Adjustment represents the net cash received from the sale of our Healthcare Services business  ($369 million of cash consideration less $7 million of estimated cash costs directly associated with the transaction).

(B)  Adjustments represent the elimination of the assets and liabilities of our Healthcare Services business that was sold.

(C)  Adjustment represents an increase in current tax liabilities of $50 million as a result of the gain recognized on the sale of our Healthcare Services business offset by the elimination of $8 million of liabilities attributable to our Healthcare Services business.

(D)  Adjustments reflect the pretax gain on the sale of our HealthCare Services business of $216 million ($166 million net of tax) calculated as follows:
 
(in millions)
     
Cash received (net of selling and other expenses)
 
$
362
 
Less:  Carrying value in Healthcare Services business
   
146
 
Pro forma gain before income tax expense
   
216
 
Less:  Income tax expense
   
50
 
Pro forma net gain on sale of our Healthcare Services business
 
$
166
 

The pro forma net gain of $166 million is reflected as an adjustment to retained earnings. This amount is based on historical information as of June 30, 2024 for Navient Corporation's carrying value of its Healthcare Services business. The actual net gain will be based on Navient Corporation's carrying value in the Healthcare Services business as of September 19, 2024.

(E)  Adjustments reflect the elimination of revenues, costs and expenses directly attributable to our Healthcare Services business.  Adjustments do not include: (1) certain general corporate and segment overhead costs previously allocated to the Healthcare Services business that will have a continuing effect on Navient post-closing or (2) any potential future cost savings that may be achieved.

(F)  Adjustment reflects the estimated income tax effect of the pro forma adjustments at the statutory rate directly related to the Healthcare Services business.


 5